Overall, our findings contribute to a better understanding of the molecular mechanisms underlying melanoma resistance to targeted therapies and provide insights into potential strategies to improve treatment outcomes for patients with BRAF- or NRAS-mutant melanomas. This evidence concerns the gene NRAS and melanoma.